JP5232350B2 - Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用 - Google Patents

Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用 Download PDF

Info

Publication number
JP5232350B2
JP5232350B2 JP2002582205A JP2002582205A JP5232350B2 JP 5232350 B2 JP5232350 B2 JP 5232350B2 JP 2002582205 A JP2002582205 A JP 2002582205A JP 2002582205 A JP2002582205 A JP 2002582205A JP 5232350 B2 JP5232350 B2 JP 5232350B2
Authority
JP
Japan
Prior art keywords
seq
repeat
sequence
polypeptide
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2002582205A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005514901A5 (enExample
JP2005514901A (ja
Inventor
ティモシー オブライエン
ジョン ビアード
ロウエル アンダーウッド
Original Assignee
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/965,738 external-priority patent/US7309760B2/en
Application filed by ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー filed Critical ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー
Publication of JP2005514901A publication Critical patent/JP2005514901A/ja
Publication of JP2005514901A5 publication Critical patent/JP2005514901A5/ja
Application granted granted Critical
Publication of JP5232350B2 publication Critical patent/JP5232350B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002582205A 2001-04-17 2002-04-12 Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用 Expired - Fee Related JP5232350B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US28417501P 2001-04-17 2001-04-17
US60/284,175 2001-04-17
US29938001P 2001-06-19 2001-06-19
US60/299,380 2001-06-19
US09/965,738 US7309760B2 (en) 2001-04-17 2001-09-27 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US09/965,738 2001-09-27
US34518001P 2001-12-21 2001-12-21
US60/345,180 2001-12-21
PCT/US2002/011734 WO2002083866A2 (en) 2001-04-17 2002-04-12 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions

Publications (3)

Publication Number Publication Date
JP2005514901A JP2005514901A (ja) 2005-05-26
JP2005514901A5 JP2005514901A5 (enExample) 2007-02-22
JP5232350B2 true JP5232350B2 (ja) 2013-07-10

Family

ID=30003964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582205A Expired - Fee Related JP5232350B2 (ja) 2001-04-17 2002-04-12 Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用

Country Status (7)

Country Link
US (1) US8124728B2 (enExample)
EP (1) EP1414477B1 (enExample)
JP (1) JP5232350B2 (enExample)
AU (1) AU2002254615A1 (enExample)
CA (1) CA2443617C (enExample)
MX (1) MXPA03009510A (enExample)
WO (1) WO2002083866A2 (enExample)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5232350B2 (ja) 2001-04-17 2013-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
MXPA05003884A (es) 2002-10-16 2005-10-05 Euro Celtique Sa Anticuerpos que enlazan polipeptidos ca 125/0772p a celulas asociadas y metodos de uso de los mismos.
JP2006516189A (ja) * 2002-11-15 2006-06-29 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Ｃａ１２５遺伝子、および診断および治療のためのその使用
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
US8404803B2 (en) 2005-03-31 2013-03-26 Chugai Seiyaku Kabushiki Kaisha Cancer-associated antigen analogue peptides and uses thereof
AU2007211085A1 (en) * 2006-01-27 2007-08-09 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
US8097242B2 (en) * 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
CL2008002083A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; inmunoconjugado; metodo in vitro para determinar presencia de cd79b, inhibir crecimiento de celula con cd79b, o para detectara celula b; metodo para elaborar dicho anticyerpo humanizado; acido nucleico; celula huesped; composicion; metodo de elaboracion de inmunoconjugado; uso medico
NZ583367A (en) 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
MX336540B (es) 2010-06-08 2016-01-22 Genentech Inc Conjugados y anticuerpos manipulados geneticamente con cisteina.
ES2544608T3 (es) 2010-11-17 2015-09-02 Genentech, Inc. Conjugados de anticuerpo y de alaninil-maitansinol
MX2013013054A (es) 2011-05-12 2014-02-20 Genentech Inc Metodo de monitoreo de lc-ms/ms de reaccion multiple para detectar anticuerpos terapeuticos en muestras de animales utilizando peptidos de firma de estructura.
WO2013055987A1 (en) 2011-10-14 2013-04-18 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
MX364328B (es) 2012-10-12 2019-04-23 Medimmune Ltd Conjugados del anticuerpo pirrolobenzodiazepina.
WO2014057117A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
PL2906251T3 (pl) 2012-10-12 2018-02-28 Adc Therapeutics Sa Koniugaty pirolobenzodiazepina-przeciwciało anty-CD22
WO2014057120A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-antibody conjugates
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
HRP20181646T2 (hr) 2012-10-12 2019-08-09 Adc Therapeutics Sa Konjugati pirolobenzodiazepin - anti-psma protutijela
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
CN105246894A (zh) 2012-12-21 2016-01-13 斯皮罗根有限公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054986B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CA2928952A1 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
JP6895254B2 (ja) 2013-12-16 2021-06-30 ジェネンテック， インコーポレイテッド ペプチド模倣化合物及びその抗体−薬物コンジュゲート
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
US10077318B2 (en) 2014-09-12 2018-09-18 Genentech, Inc. Cysteine engineered antibodies and conjugates
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
CA2969689A1 (en) 2014-12-03 2016-06-09 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
EP4190817A1 (en) * 2015-03-17 2023-06-07 Memorial Sloan Kettering Cancer Center Anti-muc16 antibodies and uses thereof
DK3388075T5 (da) * 2015-03-27 2024-09-23 Immatics Biotechnologies Gmbh Hidtil ukendte peptider og kombination af peptider til anvendelse ved immunterapi mod forskellige tumorer
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
NZ741261A (en) 2015-10-02 2019-11-29 Genentech Inc Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (en) 2015-10-20 2020-07-15 Genentech, Inc. Calicheamicin-antibody-drug conjugates and methods of use
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3433621A1 (en) 2016-03-25 2019-01-30 H. Hoffnabb-La Roche Ag Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
US20170370906A1 (en) 2016-05-27 2017-12-28 Genentech, Inc. Bioanalytical analysis of site-specific antibody drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
CN109690315A (zh) 2016-07-08 2019-04-26 豪夫迈·罗氏有限公司 人附睾蛋白4(he4)用于评估muc16阳性癌症治疗的响应性的用途
WO2018031662A1 (en) 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
HRP20221202T1 (hr) * 2016-09-23 2022-12-09 Regeneron Pharmaceuticals, Inc. Anti-muc16 (mucin 16) antitijela
JP7050770B2 (ja) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗体薬物コンジュゲートの調製方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
KR102687092B1 (ko) * 2016-10-27 2024-07-22 엘지디스플레이 주식회사 표시장치 및 그 제조방법
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
UA125198C2 (uk) 2017-02-08 2022-01-26 Ейдісі Терапьютікс Са Кон'югати піролобензодіазепін-антитіло
SI3612537T1 (sl) 2017-04-18 2022-10-28 Medimmune Limited Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
JP7145891B2 (ja) 2017-06-14 2022-10-03 アーデーセー セラピューティクス ソシエテ アノニム 抗ｃｄ１９ ａｄｃを投与するための投与レジメ
BR112020003003A2 (pt) 2017-08-18 2020-08-11 Medimmune Limited conjugados de pirrolobenzodiazepina
AU2018337815A1 (en) 2017-09-20 2020-03-12 Ph Pharma Co., Ltd. Thailanstatin analogs
WO2019118764A1 (en) * 2017-12-13 2019-06-20 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting muc16 and uses thereof
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
WO2020086858A1 (en) 2018-10-24 2020-04-30 Genentech, Inc. Conjugated chemical inducers of degradation and methods of use
EP3894427A1 (en) 2018-12-10 2021-10-20 Genentech, Inc. Photocrosslinking peptides for site specific conjugation to fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
JP2026502860A (ja) 2022-12-23 2026-01-27 ジェネンテック， インコーポレイテッド セレブロン分解剤コンジュゲートおよびその使用
CN121263210A (zh) 2023-04-17 2026-01-02 沛科生物公司 抗体和抗体-药物偶联物以及使用方法和合成工艺及中间体
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
WO1994025482A1 (en) * 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US5866402A (en) * 1995-05-05 1999-02-02 Chiron Corporation Chimeric MCP and DAF proteins with cell surface localizing domain
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6468546B1 (en) * 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) * 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US20030091580A1 (en) * 2001-06-18 2003-05-15 Mitcham Jennifer L. Compositions and methods for the therapy and diagnosis of ovarian cancer
EP1165784A2 (en) * 1999-03-31 2002-01-02 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
EP1074617A3 (en) * 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
GB9929464D0 (en) * 1999-12-13 2000-02-09 Proteom Ltd Complementary peptide ligande generated from the human genome
US6451602B1 (en) 2000-03-02 2002-09-17 Isis Pharmaceuticals, Inc. Antisense modulation of PARP expression
EP1268541A1 (en) * 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
WO2001090366A2 (en) * 2000-05-24 2001-11-29 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
WO2001092523A2 (en) * 2000-05-30 2001-12-06 Curagen Corporation Human polynucleotides and polypeptides encoded thereby
AU2001266787A1 (en) * 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030096238A1 (en) * 2000-08-17 2003-05-22 Susana Salceda Compositions and methods relating to gynecologic cancer specific genes
AU2002258518A1 (en) * 2001-03-14 2002-09-24 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7309760B2 (en) 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
JP5232350B2 (ja) 2001-04-17 2013-07-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用
US7205142B2 (en) * 2001-05-11 2007-04-17 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
WO2002092836A2 (en) * 2001-05-11 2002-11-21 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
WO2003025148A2 (en) * 2001-09-19 2003-03-27 Nuvelo, Inc. Novel nucleic acids and polypeptides
CA2461280A1 (en) * 2001-09-24 2003-04-10 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
EP1414477A4 (en) 2005-03-23
MXPA03009510A (es) 2005-04-29
AU2002254615A1 (en) 2002-10-28
US20070015907A1 (en) 2007-01-18
CA2443617C (en) 2013-12-10
WO2002083866A2 (en) 2002-10-24
EP1414477B1 (en) 2015-06-10
WO2002083866A3 (en) 2004-02-19
CA2443617A1 (en) 2002-10-24
US8124728B2 (en) 2012-02-28
JP2005514901A (ja) 2005-05-26
EP1414477A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
JP5232350B2 (ja) Ｃａ１２５遺伝子のリピート配列並びに診断および治療的介入のためのその使用
US20090035819A1 (en) CA125 gene and its use for diagnostic and therapeutic interventions
AU698823B2 (en) DNA sequence and encoded mammary-specific breast cancer protein
EP0972201B1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
EP2300041B1 (en) Method for determining risk of recurrence of prostate cancer
EP1064372B1 (en) Compounds and methods for therapy and diagnosis of lung cancer
JP4558948B2 (ja) 卵巣癌において過剰発現される膜貫通型セリンプロテアーゼおよびその使用
JP2002516659A (ja) 肺癌の治療および診断のための化合物、およびそれらの使用方法
US20030124551A1 (en) Agents implicated in endometriosis
EP2340845B1 (en) Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
JP2004529847A (ja) ｐ１８５ＨＥＲ−２またはＥＧＦ受容体を細胞内において発現する択一的なＨＥＲ−２／ＮＥＵ産物であるハースタチンの発現は受容体の活性と細胞の増殖を抑制する
JP2002517244A (ja) 前立腺癌において示差的に調節される遺伝子および遺伝子発現産物
US20050112705A1 (en) Variants of human kallikrein-2 and kallikrein-3 and uses thereof
US6387697B1 (en) Compositions for treatment and diagnosis of breast cancer and methods for their use
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
JP2004187620A (ja) 腎疾患の疾患マーカーおよびその利用
JP2003507029A (ja) Ｎｏｔｃｈレセプターリガンドおよびその使用
JPH11503904A (ja) セルブレビン・ホモログ
WO2006014903A2 (en) Compositions and methods of use for adam12 antagonists in treating disease
CN111808938A (zh) Atp6v0d2用于动脉粥样硬化的早期诊断或疗效监控
US7008772B1 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
US7355025B2 (en) Marker molecules associated with lung tumors
WO2002010338A2 (en) Expression of gage/page-like protein in benign prostatic hyperplasia
WO1998048014A1 (en) Cancer marker
MXPA97009364A (en) Sequence of desoxirribonucleico acid and specific codified breast protein to detect m cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050412

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080930

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090811

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090909

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20090914

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20100115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110816

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120612

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130325

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees